Phase I Clinical Trial in Healthy Adult
Condition: COVID-19 Intervention: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Sponsors: CanSino Biologics Inc.; Beijing Institute of Biotechnology; Jiangsu Province Centers for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention; Tongji Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenoviruses | Biotechnology | Centers for Disease Control and Prevention (CDC) | Clinical Trials | Coronavirus | COVID-19 | Hospitals | Research | Vaccines